Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Nephrology · IgA Nephropathy

What Is the Four-Hit Model of IgA Nephropathy? Explained

At a Glance

The four-hit model explains how galactose-deficient IgA1 can trigger autoantibodies, form immune complexes, and deposit in kidney filters. These deposits may cause inflammation, blood or protein in the urine, and scarring, but the model alone cannot predict an individual's outcome.

The “four-hit model” is a leading framework that helps explain the biology of how IgA nephropathy develops. It is not a diagnostic test, but rather a useful step-by-step description of the biological process that can lead to kidney injury [1][2].

It is important to know that this disease is complex. Genetic, mucosal, and environmental factors also influence who develops it, and not everyone with the first “hit” will go on to develop kidney disease [3].

The Four Hits Explained

  1. Hit 1: Altered IgA Production. The immune system produces an antibody called Immunoglobulin A1 (IgA1) to help fight infections. In people with IgA nephropathy, the body produces an increased proportion of IgA1 molecules that are missing certain sugar molecules (galactose) in a specific area. This is called galactose-deficient IgA1 [4][1].
  2. Hit 2: Autoantibodies Target the Altered IgA. Some people’s immune systems produce autoantibodies—antibodies that mistakenly react to the person’s own tissues or molecules. In this case, these autoantibodies recognize the altered sugar pattern on the galactose-deficient IgA1 and bind to it [4][1].
  3. Hit 3: Immune Complexes Form. When the autoantibodies bind to the galactose-deficient IgA1 in the bloodstream, they link together to form clusters called circulating immune complexes [4][1].
  4. Hit 4: Deposition in the Kidneys. Some of these circulating immune complexes travel to the kidneys and deposit (build up) in the mesangium. The mesangium is the supportive tissue located between the delicate capillary loops of the kidney’s filtering units (glomeruli) [4][1].

How the Four Hits Can Lead to Kidney Damage

Once the immune complexes accumulate in the mesangium, they can trigger a cascade of events that injure the kidneys:

  • Complement Activation and Inflammation: The deposited complexes can activate the complement system, a part of the immune system that promotes inflammation. This can cause the cells in the mesangium to become irritated, multiply, and release inflammatory chemicals [5][6].
  • Hematuria (Blood in the Urine): Inflammation can damage the glomerular filtration barrier. When this barrier is damaged, red blood cells can leak into the urine. This is why many patients experience visible or microscopic blood in their urine, especially during active inflammation [7][8].
  • Proteinuria (Protein in the Urine): Inflammation can also injure podocytes (specialized filtering cells) and alter the pressure in the filter, allowing essential proteins to leak into the urine [9][10]. Persistent protein in the urine is a central marker of ongoing kidney damage and a key predictor of long-term risk [11][12].
  • Scarring (Sclerosis and Fibrosis): Over time, chronic immune-mediated injury can lead to permanent damage. This includes scarring within the filtering units (segmental glomerulosclerosis) and in the surrounding kidney tissue (tubulointerstitial fibrosis), which progressively reduces the kidneys’ ability to filter waste [10][13].

What This Means for Your Diagnosis and Care

While the four-hit model explains the disease process, doctors do not routinely test your blood or urine for these four hits to make decisions about your care. The model cannot by itself predict your individual outcome [1][2].

Instead, a diagnosis of IgA nephropathy is usually confirmed with a kidney biopsy when clinically appropriate. The biopsy allows doctors to look directly at the IgA deposits and assess the extent of active injury and permanent scarring (often summarized as an Oxford MEST-C score) [14][2].

To estimate your risk and guide treatment, your care team will monitor your kidney function (eGFR), blood pressure, and the amount of protein in your urine (usually measured as a protein-to-creatinine or albumin-to-creatinine ratio).

Safety Note: Contact your clinical team if you notice new visible blood in your urine, severe swelling, a substantial drop in urine output, or shortness of breath. While dark urine can happen during a respiratory infection, it is always best to report new symptoms to your doctor.

Common questions in this guide

What are the four hits in IgA nephropathy?
The model describes four linked steps: the body makes galactose-deficient IgA1, autoantibodies recognize it, immune complexes form in the bloodstream, and some complexes deposit in the kidney's mesangium. These deposits can start inflammation and kidney injury, but having the first step alone does not mean a person will develop IgA nephropathy.
What does galactose-deficient IgA1 mean?
It is a form of IgA1 with an altered sugar pattern in a specific area of the molecule. In the four-hit model, this change can make IgA1 a target for autoantibodies, which may then help form immune complexes.
How can immune complexes cause kidney damage in IgA nephropathy?
When immune complexes collect in the mesangium, they can activate the complement system and trigger inflammation. The resulting injury may allow red blood cells and protein to enter the urine, and persistent inflammation can lead to permanent kidney scarring.
Can doctors diagnose IgA nephropathy by testing for the four hits?
No. The four-hit model explains disease biology but is not a routine blood or urine test used by itself to diagnose the condition or predict an individual's outcome. When clinically appropriate, a kidney biopsy can confirm IgA deposits and show active injury or scarring, often summarized with an Oxford MEST-C score.
What tests help monitor the effects of IgA nephropathy?
Doctors typically follow eGFR, blood pressure, and urine protein, often using protein-to-creatinine or albumin-to-creatinine ratios. A kidney biopsy report, including the Oxford MEST-C score when available, can add information about active inflammation and permanent scarring.
When should I contact my care team about possible IgA nephropathy symptoms?
Contact your clinical team if you develop new visible blood in the urine, severe swelling, a substantial drop in urine output, or shortness of breath. Dark or tea-colored urine during or after an infection should also be reported, even if it later improves.

Get notified when new evidence is published on Immunoglobulin A nephropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis.

    Suzuki H

    Clinical and experimental nephrology 2019; (23(1)):26-31 doi:10.1007/s10157-018-1582-2.

    PMID: 29740706
  2. 2

    Diagnosing and Treating IgAN: Steroids, Budesonide, or Maybe Both?

    Keskinis C, Moysidou E, Christodoulou M, et al.

    Diagnostics (Basel, Switzerland) 2024; (14(5)) doi:10.3390/diagnostics14050512.

    PMID: 38472984
  3. 3

    TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.

    Makita Y, Suzuki H, Kano T, et al.

    Kidney international 2020; (97(2)):340-349 doi:10.1016/j.kint.2019.08.022.

    PMID: 31748116
  4. 4

    Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment.

    Knoppova B, Reily C, King RG, et al.

    Journal of clinical medicine 2021; (10(19)) doi:10.3390/jcm10194501.

    PMID: 34640530
  5. 5

    The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.

    Knoppova B, Reily C, Maillard N, et al.

    Frontiers in immunology 2016; (7()):117 doi:10.3389/fimmu.2016.00117.

    PMID: 27148252
  6. 6

    Current Understanding of the Role of Complement in IgA Nephropathy.

    Maillard N, Wyatt RJ, Julian BA, et al.

    Journal of the American Society of Nephrology : JASN 2015; (26(7)):1503-12 doi:10.1681/ASN.2014101000.

    PMID: 25694468
  7. 7

    Microscopic hematuria in IgA nephropathy: a biomarker of disease activity.

    Floege J, Fervenza FC, Coppo R

    Clinical kidney journal 2026; (19(2)):sfag003 doi:10.1093/ckj/sfag003.

    PMID: 41704425
  8. 8

    Role of Palatine Tonsil and Epipharyngeal Lymphoid Tissue in the Development of Glomerular Active Lesions (Glomerular vasculitis) in Immunoglobulin A Nephropathy.

    Hotta O, Ieiri N, Nagai M, et al.

    International journal of molecular sciences 2022; (23(2)) doi:10.3390/ijms23020727.

    PMID: 35054911
  9. 9

    IgA nephropathy.

    Lai KN, Tang SC, Schena FP, et al.

    Nature reviews. Disease primers 2016; (2()):16001 doi:10.1038/nrdp.2016.1.

    PMID: 27189177
  10. 10

    Podocytopathy in the mesangial proliferative immunoglobulin A nephropathy: new insights into the mechanisms of damage and progression.

    Trimarchi H, Coppo R

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019; (34(8)):1280-1285 doi:10.1093/ndt/gfy413.

    PMID: 30698804
  11. 11

    Contemporary review of IgA nephropathy.

    Filippone EJ, Gulati R, Farber JL

    Frontiers in immunology 2024; (15()):1436923 doi:10.3389/fimmu.2024.1436923.

    PMID: 39188719
  12. 12

    A cross-sectional study in patients with IgA nephropathy of correlations between clinical data and pathological findings at the time of renal biopsy: a Japanese prospective cohort study.

    Kamano C, Shimizu A, Joh K, et al.

    Clinical and experimental nephrology 2021; (25(5)):509-521 doi:10.1007/s10157-021-02022-x.

    PMID: 33595730
  13. 13

    Treatment of IgA Nephropathy: A Rapidly Evolving Field.

    El Karoui K, Fervenza FC, De Vriese AS

    Journal of the American Society of Nephrology : JASN 2024; (35(1)):103-116 doi:10.1681/ASN.0000000000000242.

    PMID: 37772889
  14. 14

    The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.

    Rizk DV, Maillard N, Julian BA, et al.

    Frontiers in immunology 2019; (10()):504 doi:10.3389/fimmu.2019.00504.

    PMID: 30941137

This page explains the four-hit model of IgA nephropathy for informational purposes only and does not constitute medical advice. Your nephrology team should interpret your biopsy, test results, and symptoms.